CTAD 2026: AriBio’s Alzheimer’s candidate slows cognitive decline as monotherapy
AriBio’s Alzheimer’s asset hit one of the dual endpoints in a Phase 3 trial, slowing cognitive decline by 31% when…
AriBio’s Alzheimer’s asset hit one of the dual endpoints in a Phase 3 trial, slowing cognitive decline by 31% when…